CONCLUSION : Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .
O O O O O O O O O B-ChemicalEntity O O O O O O O O B-ChemicalEntity O O O O O O B-ChemicalEntity O O O O O O O O O O O O O O O O O